Maxcyte (MXCT) Total Liabilities (2019 - 2026)

Maxcyte (MXCT) has 8 years of Total Liabilities data on file, last reported at $26.6 million in Q1 2026.

• Quarterly Total Liabilities fell 12.97% year-over-year to $26.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.6 million (down 12.97% YoY) and the FY2025 annual result came in at $31.0 million, down 6.63% from the prior year.
• Total Liabilities eased to $26.6 million in Q1 2026 per MXCT's latest filing, from $31.0 million in the prior quarter.
• Across five years, Total Liabilities topped out at $36.1 million in Q4 2023 and bottomed at $26.6 million in Q1 2026.
• The 5-year median for Total Liabilities is $32.0 million (2022), against an average of $31.8 million.
• The widest annual swing landed in 2022, when Total Liabilities surged 135.6%; it then dropped 12.97% in 2026.
• Tracing MXCT's Total Liabilities over 5 years: stood at $32.7 million in 2022, then increased by 10.47% to $36.1 million in 2023, then declined by 8.0% to $33.2 million in 2024, then retreated by 6.63% to $31.0 million in 2025, then fell by 14.28% to $26.6 million in 2026.
• Per Business Quant, the three latest MXCT Total Liabilities figures stand at $26.6 million (Q1 2026), $31.0 million (Q4 2025), and $33.2 million (Q3 2025).

Peer Comparison